Xuan Zhang1, Bingbing Xie2, Yanling He1. 1. Department of Dermatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. 2. Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.
Abstract
Importance: Nail involvement is a common condition in patients with psoriasis. The treatment of nail psoriasis is considered challenging and is often left untreated by physicians. Objective: To assess the efficacy of current systemic treatments on nail psoriasis. Data Sources: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for relevant articles from inception to September 1, 2020. Included articles were restricted to English language and human studies. Study Selection: This was a systematic literature review with meta-analysis. Thirty-five random control trials that evaluated systemic therapies for nail psoriasis were selected in the systemic review. Among them, we retained 14 trials for meta-analysis. Data Extraction and Synthesis: This study was conducted in accordance with the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. All steps were performed by two independent investigators, and any disagreements were resolved by a third investigator. Meta-analysis of aggregated study data was conducted to assess therapeutic efficacy. The use of random-effects model was based on high heterogeneity as a variable endpoint in different studies. Main Outcomes and Measures: Therapeutic effects on nail psoriasis were expressed in terms of effect sizes with 95% CIs. Results: We included 35 random control trials (RCTs) in this systemic review. At baseline, a high prevalence (62.1%) of nail psoriasis was confirmed. The meta-analysis included 14 trials highlighting that biologic and small-molecule therapies were effective in treating nail psoriasis with variable effect size magnitudes [-0.89 (-1.10, -0.68), I 2 = 84%]. In particular, tofacitinib and ixekizumab showed the most significant scale of effect size magnitudes in treating nail psoriasis (-1.08 points and -0.93 points, respectively). We also found that a higher dose of tofacitinib and ixekizumab had similar effectiveness, and anti-IL-17 agents seem to be superior in effectiveness compared to anti-TNF-α therapies in the treatment of nail psoriasis. However, these results must be displayed carefully as variable endpoints in different studies. Conclusions and Relevance: This study provides a comprehensive overview of systemic treatments for nail psoriasis. For patients with psoriatic nail damage who are candidates of systemic therapies, the priority should be given to administering biologic and small-molecule therapies, especially anti-IL-17 drugs.
Importance: Nail involvement is a common condition in patients with psoriasis. The treatment of nailpsoriasis is considered challenging and is often left untreated by physicians. Objective: To assess the efficacy of current systemic treatments on nailpsoriasis. Data Sources: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for relevant articles from inception to September 1, 2020. Included articles were restricted to English language and human studies. Study Selection: This was a systematic literature review with meta-analysis. Thirty-five random control trials that evaluated systemic therapies for nailpsoriasis were selected in the systemic review. Among them, we retained 14 trials for meta-analysis. Data Extraction and Synthesis: This study was conducted in accordance with the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. All steps were performed by two independent investigators, and any disagreements were resolved by a third investigator. Meta-analysis of aggregated study data was conducted to assess therapeutic efficacy. The use of random-effects model was based on high heterogeneity as a variable endpoint in different studies. Main Outcomes and Measures: Therapeutic effects on nailpsoriasis were expressed in terms of effect sizes with 95% CIs. Results: We included 35 random control trials (RCTs) in this systemic review. At baseline, a high prevalence (62.1%) of nailpsoriasis was confirmed. The meta-analysis included 14 trials highlighting that biologic and small-molecule therapies were effective in treating nailpsoriasis with variable effect size magnitudes [-0.89 (-1.10, -0.68), I 2 = 84%]. In particular, tofacitinib and ixekizumab showed the most significant scale of effect size magnitudes in treating nailpsoriasis (-1.08 points and -0.93 points, respectively). We also found that a higher dose of tofacitinib and ixekizumab had similar effectiveness, and anti-IL-17 agents seem to be superior in effectiveness compared to anti-TNF-α therapies in the treatment of nailpsoriasis. However, these results must be displayed carefully as variable endpoints in different studies. Conclusions and Relevance: This study provides a comprehensive overview of systemic treatments for nailpsoriasis. For patients with psoriatic nail damage who are candidates of systemic therapies, the priority should be given to administering biologic and small-molecule therapies, especially anti-IL-17 drugs.
Authors: Peter Foley; Kenneth Gordon; Christopher E M Griffiths; Yasmine Wasfi; Bruce Randazzo; Michael Song; Shu Li; Yaung-Kaung Shen; Andrew Blauvelt Journal: JAMA Dermatol Date: 2018-06-01 Impact factor: 10.282
Authors: A L Tan; M Benjamin; H Toumi; A J Grainger; S F Tanner; P Emery; D McGonagle Journal: Rheumatology (Oxford) Date: 2006-07-11 Impact factor: 7.580
Authors: K A Papp; M A Menter; M Abe; B Elewski; S R Feldman; A B Gottlieb; R Langley; T Luger; D Thaci; M Buonanno; P Gupta; J Proulx; S Lan; R Wolk Journal: Br J Dermatol Date: 2015-10 Impact factor: 9.302
Authors: Richard B Warren; Ulrich Mrowietz; Ralph von Kiedrowski; Johannes Niesmann; Dagmar Wilsmann-Theis; Kamran Ghoreschi; Ina Zschocke; Thomas M Falk; Norbert Blödorn-Schlicht; Kristian Reich Journal: Lancet Date: 2016-12-22 Impact factor: 79.321
Authors: C Paul; J Cather; M Gooderham; Y Poulin; U Mrowietz; C Ferrandiz; J Crowley; C Hu; R M Stevens; K Shah; R M Day; G Girolomoni; A B Gottlieb Journal: Br J Dermatol Date: 2015-11-07 Impact factor: 9.302
Authors: K Reich; J Sullivan; P Arenberger; U Mrowietz; S Jazayeri; M Augustin; A Parneix; P Regnault; R You; M Milutinovic Journal: Br J Dermatol Date: 2019-01-16 Impact factor: 9.302
Authors: Philip J Mease; Désirée van der Heijde; Christopher T Ritchlin; Masato Okada; Raquel S Cuchacovich; Catherine L Shuler; Chen-Yen Lin; Daniel K Braun; Chin H Lee; Dafna D Gladman Journal: Ann Rheum Dis Date: 2016-08-23 Impact factor: 19.103